Research context
DSIP Dosage: What the Studies Administered, and How Fast It Cleared
A research-context summary of the doses, routes, and pharmacokinetics reported in the delta sleep-inducing peptide literature. Not a dosing guide.
Read this first
This page describes DSIP dosage strictly as it appears in published studies — what researchers gave to which species, by which route, in which experiment. It is not a how-to and contains no recommendation for any person to take anything. DSIP is not an approved drug, there is no established human dose, and there is no validated human pharmacokinetic profile [3].
In plain terms: the doses below are measured in units like nmol/kg or micrograms/kg, which scale to body weight, and they vary enormously by route — a dose dripped directly into a rat's brain is not comparable to an injection into a vein. One thing is consistent across the data: DSIP clears from the blood extremely fast, with a measured half-life of only minutes in animals. Everything here is context for reading the research, nothing more.
DSIP dosage
Across the literature, the DSIP dosage that matters most for humans comes from sleep research: 25 nmol/kg of body weight, given intravenously, was the dose used in the six-person chronic-insomnia study and in the human stress-hormone work [2][4]. That is the single most frequently referenced human research dose.
Animal studies used a wide spread tied to the experiment. Rat stroke-recovery work used 120 micrograms/kg intranasally [9]; mitochondrial-protection work used 120 micrograms/kg by injection [8]; rat anticonvulsant studies used 0.1-1 mg/kg, most effective at 1 mg/kg [7]; and the mouse longevity work used a DSIP-containing preparation at about 100 micrograms/kg, given five consecutive days each month [5]. These numbers describe experiments, not protocols for people.
DSIP peptide dosage and the parabolic dose-response
A genuinely unusual feature of DSIP peptide dosage is that more is not reliably better. The literature reports a parabolic (bell-shaped, or non-monotonic) dose-response, in which intermediate doses can outperform high ones. In a rat thermoregulation study, for instance, the effect followed an inverted bell curve, with a minimal effective dose around 10 ng and a maximal effect near 1 microgram [12].
This matters for interpreting any DSIP study: a result at one dose does not predict the result at a higher dose, and scaling up can reduce rather than increase an effect. It is one more reason the research is hard to translate, and one more reason that community claims about 'the right amount' have no validated basis.
DSIP peptide nasal spray and routes studied
Route matters a great deal for a peptide this fragile. The routes that appear in the research include intravenous (human and animal) [2], intracerebroventricular — directly into the brain's fluid spaces — in rodents [1], subcutaneous (under the skin) in cats and mice [5], and intranasal in the rat stroke work [9]. The intranasal route is the basis of community interest in a DSIP peptide nasal spray, since the rat neuroprotection result used nasal delivery at 120 micrograms/kg [9]; note that the rat study is not a human product and says nothing about a safe or effective human nasal dose.
The practical backdrop is fragility. DSIP is a short peptide, rapidly broken down by enzymes in plasma, which is why its measured half-life is only minutes.
DSIP half-life and stability
DSIP's half-life — the time for its blood level to fall by half — is very short. A metabolic-clearance study using enzyme immunoassay in dogs, monkeys, and rats reported plasma half-lives on the order of only a few minutes, attributed to rapid degradation by aminopeptidases (enzymes that chop peptides apart) and plasma proteins. No validated human pharmacokinetic profile exists [3].
That fragility shapes everything. The naturally phosphorylated form (DSIP-P) and various synthetic analogs are reported to be more stable or potent in some assays, which dovetails with the 2006 review's observation that analogs, not native DSIP, often drove the clearest effects [3]. As a research material, DSIP is typically supplied lyophilized (freeze-dried) and reconstituted in sterile water for lab use; there is no pharmaceutical-grade product and no stability standard. For what the studies actually found, see the DSIP research.